The U.S. Supreme Court has agreed to consider reinstating full access to the abortion drug mifepristone, once again entering the fraught territory of abortion litigation less than two years after its bombshell ruling in Dobbs.

In unexplained orders Wednesday morning, the U.S. Supreme Court granted petitions for review a Fifth Circuit opinion restricting distribution of the medication mifepristone, The petitions for review came from the U.S. Food and Drug Administration and Danco Laboratories, a company that manufactures the “abortion pill,” now the most common method of abortion in the country.